# Reports for the later measurement

> Reading list — Boston Weight Loss Clinics — The published research discussed by Boston Weight Loss Clinics, arranged around continued treatment, withdrawal, cardiovascular outcomes and tolerability.

**Reading list**

Trials of semaglutide and tirzepatide, a body-composition substudy and safety reviews, grouped by the follow-up question they take up.

## Duration, continuation and withdrawal

Begin with [the initial STEP 1 semaglutide result](https://pubmed.ncbi.nlm.nih.gov/33567185/) and [STEP 5's longer observation during treatment](https://pubmed.ncbi.nlm.nih.gov/36216945/). Then turn to [SURMOUNT-4's tirzepatide continuation-versus-withdrawal comparison](https://pubmed.ncbi.nlm.nih.gov/38078870/) and [the post hoc analysis of risk markers after withdrawal](https://pubmed.ncbi.nlm.nih.gov/41284285/).

I give the withdrawal reports unusual prominence because they ask the less comfortable sequel to an impressive initial finding.

## Cardiovascular outcomes and body composition

[SELECT](https://pubmed.ncbi.nlm.nih.gov/37952131/) examines semaglutide's cardiovascular event outcome in its defined population. [STEP-HFpEF](https://pubmed.ncbi.nlm.nih.gov/37622681/) takes up symptoms and physical limitations in obesity-related heart failure. The [SURMOUNT-1 body-composition substudy](https://pubmed.ncbi.nlm.nih.gov/39996356/) adds fat and lean mass to the tirzepatide weight question.

## Tolerability and safety

The [broader tolerability review](https://pubmed.ncbi.nlm.nih.gov/41351656/) and [Safety of Semaglutide](https://pubmed.ncbi.nlm.nih.gov/34305810/) are useful companions to the efficacy reports. [SUSTAIN-6](https://pubmed.ncbi.nlm.nih.gov/27633186/) includes the diabetes-specific retinopathy finding discussed in the tolerability essay. Full citation details follow.

## References

[1] Once-Weekly Semaglutide in Adults with Overweight or Obesity https://pubmed.ncbi.nlm.nih.gov/33567185/
[2] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial https://pubmed.ncbi.nlm.nih.gov/36216945/
[3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38078870/
[4] Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. https://pubmed.ncbi.nlm.nih.gov/41284285/
[5] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://pubmed.ncbi.nlm.nih.gov/37952131/
[6] Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/37622681/
[7] Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. https://pubmed.ncbi.nlm.nih.gov/41351656/
[8] Safety of Semaglutide https://pubmed.ncbi.nlm.nih.gov/34305810/
[9] Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. https://pubmed.ncbi.nlm.nih.gov/39996356/
[10] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27633186/

---

I follow the later chapters of published research at Boston Weight Loss Clinics, an editorial site rather than a clinical business, and nothing here supplies medical advice.